Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $21 from $22 and keeps an Overweight rating on the shares. The firm thinks the clarity on bexdeg’s 3L+ CLL pivotal trial dose plus concurrent financing removes key overhangs. With the company funded into 2028, read through from Kymera Therapeutics’ (KYMR) upcoming KT-621 Phase 1b data and a potential GILD IRAK4 opt-in decision in 2026, Wells likes the setup.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX: